# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target fr...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $120 pri...
RBC Capital analyst Leonid Timashev initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Outperform rating and announ...
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...
Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...